



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/870,902	05/31/2001	Jonathan Robert Lamb	7755		
7590 04/09/2004			EXAMINER		
Pillsbury Winthrop LLP.			EWOLDT, GERALD R		
Intellectual prop	erty group o Real, Suite 200	ART UNIT	PAPER NUMBER		
San Diego, CA		1644			
			DATE MAILED: 04/09/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application N		Applicant(s)				
Office Action Summary		Application N						
		09/870,902		LAMB ET AL.	<u>. </u>			
		Examiner		Art Unit				
		G. R. Ewoldt,		1644				
Period fo	The MAILING DATE of this commun or Reply	ication appears on the co	ver sheet with the c	correspondence address	;			
THE - External after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD F MAILING DATE OF THIS COMMUNI nsions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comm period for reply specified above is less than thirty (3 period for reply is specified above, the maximum state to reply within the set or extended period for reply reply received by the Office later than three months a ded patent term adjustment. See 37 CFR 1.704(b).	CATION. of 37 CFR 1.136(a). In no event, h nunication. 0) days, a reply within the statutory atutory period will apply and will exp will, by statute, cause the application	nowever, may a reply be tin minimum of thirty (30) day bire SIX (6) MONTHS from on to become ABANDONE	nely filed s will be considered timely. the mailing date of this communi D (35 U.S.C. § 133).	ication.			
Status								
1) 🏻	Responsive to communication(s) file	d on <i>20 January 2004</i> .						
,	This action is FINAL . 2b)⊠ This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
5) 6) 7)	Claim(s) <u>2,4-13,17,19,20,25,27,30 a</u> 4a) Of the above claim(s) is/a Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>2,4-13,17,19,20,25,27,30 a</u>	re withdrawn from consic	deration.	ion requirement.				
Applicat	ion Papers							
9)[The specification is objected to by th	e Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.								
	Applicant may not request that any obje							
11)	Replacement drawing sheet(s) including The oath or declaration is objected to	•						
Priority (ınder 35 U.S.C. § 119							
a)	Acknowledgment is made of a claim All b) Some * c) None of: 1. Certified copies of the priority 2. Certified copies of the priority 3. Copies of the certified copies application from the Internation	documents have been re documents have been re of the priority documents anal Bureau (PCT Rule 1	eceived. eceived in Applicati s have been receive 7.2(a)).	ion No ed in this National Stag	e			
Attachmen	t(s)							
_	e of References Cited (PTO-892)	4)	☐ Interview Summary					
2) Notice 3) Information	ee of Draftsperson's Patent Drawing Review (F mation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date	PTO/SB/08) 5)	Paper No(s)/Mail D. Notice of Informal F Other:	ate Patent Application (PTO-152)				

DETAILED ACTION

- 1. In the amendment filed 1/20/04 the claims have been amended such that a new restriction is required.
- 2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- I. Claims 2, 4-9, 19-20, 25, and 27, drawn to method for producing a regulatory lymphocyte comprising contacting a lymphocyte with a primed APC, classified in Class 435, subclass 372.
- II. Claims 10-11, 13, and 30, drawn to method for producing a regulatory lymphocyte comprising contacting a lymphocyte with a regulatory lymphocyte, classified in Class 435, subclass 372.3.
- III. Claims 12, 17, and 32, drawn to a method for suppressing an immune response or treating a patient suffering from a disease characterized by inappropriate lymphocyte activity comprising administering a regulatory lymphocyte to a patient or mammal, classified in Class 424, subclass 93.71.
- 3. Inventions I-III are different methods. In vivo methods of treating patients (Group III) comprise significantly different process steps and endpoints than do in vitro methods (Groups I and II). Groups I and II differ in that they employ different regents (a lymphocyte, e.g., a T cell, versus an APC) to produce a regulatory lymphocyte. Therefore they are patentably distinct.
- 4. This application contains inventions drawn to patentably distinct species. Regardless of Group chosen, Applicant is further required under 35 U.S.C. § 121 to elect:
- A) a **specific** substance for upregulating expression of Notch or a Notch ligand, such as those listed in Claims 46 or 7,
- B) Notch or a **specific** Notch ligand, such as one of those listed in Claim 8.
- C) and list all Claims readable thereon including those subsequently added. Currently all claims are generic.
- 5. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of

Serial No. 09/870,902 Art Unit 1644

the other invention.

The different substances for upregulating expression of Notch or a Notch ligand comprise significantly different biological activities. For example, Noggin and IL-4 comprise unrelated molecules with unrelated functions on different cell types. Notch, versus ligands which bind Notch, also comprise unrelated molecules. The various Notch ligands comprise different activating capabilities under different conditions. Therefore, the species are independent and patentable over one another.

- 6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 7. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

Please Note: Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

G.R. Ewoldt, Ph.D. Primary Examiner Technology Center 1600

G.R. EWOLDT, PH.D. PRIMARY EXAMINER